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ABSTRACT
Background: Providing care for people who are co­infected with both HIV and hepatitis C virus (HCV) is becoming increasingly
complex and requires integrated prevention, screening, support and programming efforts. We undertook a scoping review to
provide a summary of the existing evidence base and to identify and assess the quality of treatment guidelines and systematic
reviews related to 3 domains of interest: treatment; epidemiology; and care, support, programming and prevention.
Methods: We searched 7 databases, hand­searched 8 journals and contacted key informants to identify relevant literature. We
included all primary research (including systematic reviews and meta­analyses) or treatment guidelines that assessed pegylated
interferon and ribavirin for HCV or highly active antiretroviral therapy for HIV treatment, or both. In the epidemiology domain,
we included all primary research (including systematic reviews and meta­analyses). Studies that included only people with
hemophilia and those conducted in developing countries were excluded. In the care, support, programming and prevention
domain, we included all studies and reports that focused on co­infection. Two reviewers independently applied coding criteria
and assessed the quality of the treatment guidelines and systematic reviews using the Appraisal of Guidelines Research and
Evaluation and A MeaSurement Tool to Assess Reviews instruments.
Results: Our search strategy yielded 1633 unique references. Of these, 227 references met the final inclusion criteria: 114
addressed treatment, 52 epidemiology and 79 care, support, programming or prevention. The references included 9 treatment
guidelines: 4 were assessed as “strongly recommend,” 3 as “recommend (with provisos or alterations)” and 1 as “would not
recommend” (1 could not be located). Of 10 systematic reviews that were located, 7 were assessed as being high quality, 2 as
medium quality and 1 as low quality.
Conclusion: This quality­assessed inventory of treatment guidelines and systematic reviews can be used by physicians and service
providers to rapidly locate research about HIV–HCV co­infection. However, many treatment guidelines and reviews often
indicate that treatment of current injection drug users and/or people with mental health issues should proceed on a “case­by­case
basis.” Therefore, much of the evidence (particularly in the treatment literature) is limited in its scope and applicability to
important populations that are vulnerable to HIV or HCV infection or co­infection.
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T
HE AVAILABILITY AND ACCESSIBILITY OF HIGHLY
active antiretroviral therapy (HAART) in Canada
has extended the length and improved the
quality of life of people with HIV.
1,2 As a result,
important co­morbidities are now emerging among
people living with HIV. This has increased the
complexity of their health and health care needs.
3­5 The
hepatitis C virus (HCV) commonly affects people with
HIV and is a leading cause of death among people with
HIV.
1,6
Currently in Canada, it is estimated that a large
proportion (18%) of people with HIV are co­infected
with HCV.
7 The strongest predictor or risk factor of co­
infection is a history of injection drug use (IDU), with
co­infection rates estimated to range from 50% to
92%.
7­20 As a result, the populations affected most
severely by co­infection are those in which IDU is most
prevalent, such as current and former prisoners and
Aboriginal people (First Nations, Inuit and Métis).
16 For
instance, 2 separate studies in Ontario and Quebec
prisons found that the prevalence of HCV among
inmates infected with HIV was 68% and 64.8%,
respectively.
21,22
Combination HCV therapy with pegylated interferon
and ribavirin is available for some people with HIV–HCV
co­infection; however, the likelihood of treatment success
(sustained virological response, defined as plasma free of
HCV 6 months after completion of therapy) is diminished
in people with HIV–HCV co­infection (genotype 1:
˜15%–30%, genotype 2, 3: ˜55%–60%)
23,24 compared
with people infected with HCV alone (genotype 1:
˜40%–50%, genotype 2, 3: ˜70%–90%).
25,26
The design and implementation of programs to
deliver effective medical care for patients with
HIV–HCV co­infection should take into account the
differences in the psychosocial and medical status
between some individuals.
27 Research has consistently
identified substantially lower quality of life and
cognitive function and a higher prevalence of mental
illness among patients co­infected with HIV and HCV.
28
Current guidelines state that treatment for HCV
infection can be started for patients co­infected with
HIV who currently use illicit drugs or have mental
illness.
29 However, active drug use and mental illness
and their associated morbidities, such as homelessness
and lack of social support, represent an important
barrier to accessing treatment and to drug adherence.
In addition, the presence of active depression before
HCV treatment with interferon­based therapies is
highly predictive of the development of clinically
important depression during therapy, which is
associated with significantly low virological response
and low adherence rates.
30 The treatment of mental
illness in co­infected individuals before the
administration of HCV treatment represents a critical
step in the successful care and support of co­infected
patients.
In response to these complex treatment issues and
the need to support care and community service
providers who work with people who are co­infected,
we undertook a scoping review (i.e., a rapid but
rigorous assessment of the literature; see Box 1 for a
description of scoping reviews) to provide a summary of
the existing evidence base and an inventory of relevant
systematic reviews and treatment guidelines that are
currently available. Our specific objectives were to
identify and assess the quality of systematic reviews and
treatment guidelines about treatment, care, support,
programming and prevention, as well as about the
epidemiologic profile of HIV and HCV co­infection. We
describe the sources and types of available evidence,
identify areas where systematic reviews could be
completed and highlight where additional primary
research is needed.
Methods
Literature search. We used 3 strategies — database
searches, journal hand­searching and key contacts — to
identify published and unpublished literature. Our
search strategies were designed to provide a balance
between a rapid assessment of the literature and a
comprehensive survey of the literature about HIV–HCV
co­infection. First, we searched 7 databases (MEDLINE,
PubMed, Cochrane Library, PsycINFO, AIDSearch,Review Wilson et al
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contacted relevant researchers from 5 Canadian
universities (McGill University, University of Alberta,
University of British Columbia, McMaster University
and the University of Toronto) and 4 organizations in
Canada in the field of HIV and HCV (University Health
Network, Centre for Addictions and Mental Health,
Insite – Supervised Injection Site and Vancouver
Coastal Health Authority) and asked them to identify
any published and unpublished works that would be
relevant to our review.
Article review and selection. We used an iterative and
reflexive approach to develop and apply inclusion and
coding criteria to the search results. First, from the
electronic database search results, 2 pairs of
independent reviewers (MGW and a research assistant;
MD and a research assistant) reviewed the first 200
titles and abstracts retrieved and assigned each a code
based on whether the publication addressed a question
about HIV–HCV co­infection, whether it studied or
discussed a Canadian population or an international
population, the study design and the subject area
addressed. We then met as a team and created
additional codes for specific study populations and
subject areas of interest. Next, 2 pairs of independent
reviewers (MGW and a research assistant; MD and a
research assistant) reviewed all of the titles and
abstracts identified in our initial searches and excluded
those not related to HIV–HCV co­infection.
We then collectively developed inclusion criteria for
3 domains (treatment; epidemiology; and care, support,
programming and prevention) and 2 pairs of
independent reviewers (MGW and a research assistant;
MD and a research assistant) applied the inclusion
criteria to all remaining titles and abstracts. In the
treatment domain, we included all primary research
(including systematic reviews and meta­analyses) and
treatment guidelines that assessed pegylated interferon
and ribavirin for HCV (current standard of care) or
HAART for HIV treatment, or both. In the
epidemiology domain, we included primary research
(including systematic reviews and meta­analyses). For
both the treatment and epidemiology domains, we
excluded studies that included only people with
hemophilia and those conducted in developing
countries. Because of the lack of literature on care,
support, programming and prevention, for this domain
we included all studies and reports that focused on co­
infection.
Next, we collectively refined the coding framework
to include 24 characteristics across 4 categories — study
design, study population, country or region of study and
scope of study. Using the full text of each article, 2 of us
(MGW and MD) independently assigned the new codes
to each of the included references (Boxes 2–4).
Disagreements were resolved through discussion until
consensus was reached.
Last, 2 pairs of independent raters assessed the
quality of each of the included systematic reviews and
treatment guidelines (disagreements were resolved
through discussion until consensus was reached). For
systematic reviews, 2 independent raters (MGW and a
research coordinator) applied the AMSTAR (A
MeaSurement Tool to Assess Reviews) instrument,
which has strong face and content validity and has been
shown to be the strongest quality­assessment tool for
systematic reviews.
33,34 The AMSTAR instrument
produces a quality score between 0 and 11, with ranges
representing low (scores of 0–3), medium (4–7) and
high (8–11) quality.
35 For treatment guidelines, 2
independent raters (MGW and AC) applied the AGREE
(Appraisal of Guidelines Research and Evaluation)
instrument, which is designed to be used by a wide
range of professionals, demonstrates strong reliability
and is the only internationally tested instrument.
36
AGREE consists of 23 items (4­point Likert scales)
across 6 domains, which are used to produce 3 possible
conclusions: “strongly recommend,” “recommend (with
provisos or alterations)” or “would not recommend.”
37
Results
Our search strategy yielded 1633 articles (2598 before
duplicate removal). Of these, 227 met the final inclusion
criteria (Fig. 1). The full bibliography of included
articles is available at http://www.ohtn.on.ca/
Pages/Knowledge­Exchange/HIV­HCV­Scoping­
Review.aspx. Agreement for the 2 sets of reviewers
(calculated only at the inclusion­assessment stage; Fig.
1) was fair, with Kappa statistics of 0.377 and 0.249.
Of the 227 articles, 9 were treatment guidelines and
10 were systematic reviews (Table 1). Of the 9 treatment
guidelines, 4 were “strongly recommended,”
38­41 3 were
“recommended (with provisos or alterations)”
29,42,43 and
1 was classified as “would not recommend”;
44 1
guideline could not be assessed because it could not be
located.
45 Of the 10 included systematic reviews, 3
addressed topics related to treatment,
46­48 3 focused on
epidemiology,
47,49,50 4 focused on care or support
49,51­53
and 4 focused on prevention
51,52,54,55 (5 reviews
addressed more than 1 domain). Through our quality
assessments of the included systematic reviews we
found 7 to be of high quality,
46,48,51­55 with only 2 rated as
medium quality
49,50 and 1 as low quality.
47
We found 114 publications or reports in the
treatment domain, 52 in the epidemiology domain and
79 in the care, support, programming and prevention
domain (Boxes 2–4). Across all 3 domains, most of the
studies were either local or national or involved
multiple cities. Most of the treatment studies were from
Europe (n = 64) and the United States (n = 33). In theReview Wilson et al
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Canadian HIV/AIDS Policy & Law Review, and Google
Scholar) from 1996 to January 2007 using
combinations of search terms developed through
consultation with a librarian at the University of
Toronto (see for a full list of search terms). Given that
our focus was on Canadian and North American content
and that we wanted to perform a rapid assessment of
the literature, we prioritized a relatively small subset of
databases. Therefore, we selected MEDLINE and
PubMed to capture treatment­related information,
PsycINFO to capture literature related to mental health,
AIDSearch to capture additional HIV­relevant
literature, and Canadian HIV/AIDS Policy & Law
Review to identify any policy­related documents that
may not be indexed in the health sciences literature,
and Google Scholar to identify any additional grey
literature. We then hand­searched 8 journals
(Canadian Medical Association Journal, AIDS Care,
AIDS Policy and Law, Annals of Internal Medicine,
Canadian Journal of Gastroenterology, HIV Medicine,
Journal of Acquired Immune Deficiency Syndromes
and New England Journal of Medicine). These 8
journals were recommended by 2 members of our team
(CLC and AC) who deal extensively with co­infection
issues. For each journal, we reviewed all issues from
January 2000 to January 2007 and identified all
systematic reviews, treatment guidelines and primary
research that addressed treatment, epidemiology,
and/or care, support, programming and prevention for
people co­infected with HIV and HCV. We alsoReview Wilson et al
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treatment domain, we found 21 studies that included
information related to both HAART for HIV and
pegylated interferon and ribavirin treatment for HCV, 53
studies that investigated topics related only to HAART in
co­infected people and 40 studies that investigated topics
related only to pegylated interferon and ribavirin
treatment in co­infected people. In the epidemiology
domain, all of the 52 studies found included information
related to epidemiologic trends of co­infection in key
populations at high risk of HIV or HCV infection, or co­
infection. Of these studies, 24 included current and
former injection drug users, 8 included prison
populations and 5 included people who had mental
illness. In the care, support, programming and
prevention domain, 43 studies addressed topics related
to care, support and programming only, 5 addressed
topics related to prevention only and 31 addressed both
topics. More than half of the publications and
reports in this domain addressed issues
related to IDU. (A full list of the references
found for each of the 3 domains is available at
http://www.ohtn.on.ca/Pages/Knowledge­
Exchange/HIV­HCV­Scoping­Review.aspx.)
Discussion
Overall, we found that the literature on
HIV–HCV co­infection is fairly well defined.
We identified 9 treatment guidelines and 10
systematic reviews that addressed 1 or more
of the 3 topic domains, which provides those
delivering treatment, care and support with a
reliable evidence base to draw from. The
quality­assessed inventory of treatment
guidelines and systematic reviews can be
used by physicians and service providers to
rapidly determine whether there are
guidelines or reviews available that are
specific to their jurisdiction and of sufficient
quality to help with decision­making about
treatment or other service­delivery issues.
Although we found a number of treatment
guidelines and systematic reviews, many
were based on literature that did not include
current injection drug users or people with
mental health issues because of limited
evidence from these populations (especially
in the treatment literature). As a result,
guidelines and reviews often indicate that
treatment in these populations should
proceed on a “case­by­case basis.” This
finding is particularly salient given that the
epidemiologic literature indicates that co­
infection is mostly found among current and former
injection drug users.
18 Therefore, much of the evidence
(particularly in the treatment literature) either is
limited in its scope and applicability to important
populations that are vulnerable to HIV or HCV
infection or co­infection, or lacks detail about how to
deliver treatment to these populations while ensuring
appropriate supportive care. Because active drug use
and mental illness can reduce access to, adherence to
and effectiveness of treatment for both HIV and HCV
infections, programs to improve the health of co­
infected patients must include a multidisciplinary
approach using specialists in HCV and HIV treatment
for injection drug users and those with mental illness.
The main clinical trials for HCV treatment involving
HIV–HCV co­infected individuals used 800 mg per day
of ribavirin.
23,24 This is lower than the current standard
Figure 1: Study selection
* Kappa statistics were calculated only at this stage of reviewing because
when the initial coding was applied studies were excluded only if they
did not assess a topic related to HIV–HCV co‐infection, and when the
inclusion criteria were applied to the full‐text articles, each review was
reconciled through extensive discussion. Therefore, we determined that
it was most appropriate to calculate agreement only when the inclusion
criteria were first applied to all titles and abstracts.Review Wilson et al
Open Medicine 2009 3(4):1 84-1 95
of care and may have diminished the sustained
virological response obtained in these studies. In these
studies, infected participants with genotype 2 or 3
received 48 weeks of therapy. It is not clear whether
shorter treatment durations are equally effective.
Additional evaluation of alternative dosing strategies in
HIV–HCV co­infected populations is warranted. The
HIV nucleosides used for HIV treatment in these early
HCV studies (i.e., stavudine, didanosine, zidovudine)
differ from those that are now used as part of standard
practice. Each of these medications may have negative
effects on overall tolerance of HCV therapy and
sustained virological response. For example,
combination didanosine–ribavirin therapy is now
contraindicated because of increased risk of
pancreatitis.
23,56 The co­administration of zidovudine
with ribavirin is not advised because it may exacerbate
HCV treatment­related anemia and treatment­related
fatigue, and increase the need for dose reduction,
thereby diminishing sustained virological response.
57
In Canada, there are high levels of HIV–HCV co­
infection among populations at high risk of HIV and
HCV infection, such as current and former injection
drug users, people with mental health illness and
current and former prisoners. Thus, there is an
increasing need to integrate prevention, screening, care,
support and programming efforts and the funding
streams for existing programs. An integrated
programming and funding strategy will allow for
populations to receive services for care, support and
prevention, not only for HIV–HCV co­infection but also
for other co­morbidities such as IDU and mental health
issues.
The primary strengths of this scoping review are that
it provides a rigorous systematic assessment of the
literature on HIV–HCV co­infection across 3 domains,
an inventory of treatment guidelines and systematic
reviews that have been assessed for quality, a clear
sense of the populations that have been a focus in the
co­infection literature, and a direction for future
research initiatives.
Several limitations of our scoping review should be
highlighted. First, we did not include all relevant
databases, such as EMBASE and CINAHL, which may
have captured additional relevant publications that may
not be found in MEDLINE. These databases were
omitted because we wanted to conduct a relatively rapid
review of the literature. We are confident that we
captured much of the relevant literature available.
Second, the agreement between reviewers was only fair
(Kappa statistics 0.377 and 0.249). This low agreement
is likely attributable to the fact that many abstracts were
difficult to assess using our broad inclusion criteria,
especially in the treatment domain since it was often
difficult to discern the exact treatment regimen without
reviewing the full text. As a result, we were over­
inclusive at the title­ and abstract­review stage because
we deemed it more important to ensure that we did not
inadvertently exclude any relevant studies. Finally,
because we wanted to focus on Canadian and other
North American literature and to keep the review
focused and rapid, we did not consider some important
populations. Therefore, we excluded studies from
developing countries and studies that focused only on
people with hemophilia, deeming these to have
different contexts that require separate analysis.
Our findings are not meant to be an exhaustive
analysis of outcomes that would normally be found in a
systematic review but rather are an outline of the
primary themes that emerged from the systematic
reviews, treatment guidelines, longitudinal studies and
key references for care, support, programming and
prevention that were included in this review. This
outline of primary themes was prepared to provide a
broad evidence base for the multi­stakeholder think
tank that this scoping review was originally
commissioned for.
Given the limited scope of some of the literature that
we located, there is a need to expand co­infection
research initiatives (particularly in the treatment and
support domains) to injection drug users and mental
health populations and to ensure that existing
systematic reviews and treatment guidelines are
updated as new data from these initiatives emerges. In
addition, beyond the topics of methadone treatment
and needle exchange for injection drug users, the
literature about care, support, programming and
prevention appears to lack enough depth for a full
systematic review. Therefore, future research should
attempt to evaluate or highlight integrated and
interdisciplinary care models that use a harm­reduction
approach for the treatment, care and support for people
co­infected with HIV and HCV. Intervention research
would help determine prevention efforts and support
services for co­infected people and those at risk. Last,
tracking the epidemiologic profile of HIV–HCV co­
infection needs to continue with rigorous longitudinal
models.
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